What is Kodiak Sciences Inc's market cap?

Kodiak Sciences Inc (KOD) has a market capitalization of $2.6B and trades on NASDAQ.

Who are Kodiak Sciences Inc's competitors?

Kodiak Sciences Inc's key competitors include Regeneron Pharmaceuticals, Inc., Kalaris Therapeutics, Inc. Common Stock, 4D Molecular Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Kodiak Sciences Inc partner with?

Kodiak Sciences Inc's notable partners include Lonza.

Where is Kodiak Sciences Inc headquartered?

Kodiak Sciences Inc is headquartered in United States of America and employs approximately 107 people. It has been publicly traded since 2018.

Kodiak Sciences Inc

KOD

Kodiak Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing next-generation therapeutics for retinal diseases.

Market cap

$2.62B+581%

Net income-$230.7M-21.0%

Free cash flow-$148.1M-37.9%

EPS (diluted)-$4.17-14.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$0.94Miss by $0.01

Read the full report

Next report

Aug 12, 2026 (In 2 weeks)

EPS estimate-$0.97

Financials

Q1 2026

Income statement

See full

Operating income-$59.8M-1.2%

Net income-$58.2M-1.2%

EPS (diluted)-$0.94+13.8%

Balance sheet

See full

Cash & equivalents$169.5M+22.1%

Total debt$56.0M-17.2%

Total equity$112.1M+3.0%

Total assets$306.0M+2.7%

Cash flow

See full

Operating cash flow-$40.0M-37.6%

CapEx$942.0K+249%

Free cash flow-$41.0M-39.5%

Valuation & ratios

Valuation

See full

Market cap$2.62B+581%

Enterprise value$2.51B+534%

Returns & leverage

See full

Return on equity-208.8%+2,306pp

Debt / equity0.5×-0.1×

Current ratio3.5×-1.1×

Competitors

By market cap

Regeneron Pharmaceuticals$69.9B+16.0%

Kodiak Sciences Inc$2.6B+503%

HRO

Harrow$1.4B+9.1%

4D Molecular Therapeutics$542.6M+152%

Lineage Cell Therapeutics$256.8M-3.9%

Outlook Therapeutics, Inc.$199.2M+131%

KLR

Kalaris Therapeutics Inc$85.2M+55.7%

Kiora Pharmaceuticals, Inc.$11.3M+26.2%

By revenue growth

4D Molecular Therapeutics+383,561%

HRO

Harrow+26.2%

Regeneron Pharmaceuticals+5.9%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

HRO

Harrow-19.75%+1.0pp

4D Molecular Therapeutics-174,314.17%+699,167pp

Profile

Kodiak Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing next-generation therapeutics for retinal diseases. The company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to create medicines with enhanced ocular half-life and durability, aiming to reduce the treatment burden for patients with vision-threatening conditions.

Competitive position

A clinical-stage innovator focused on high-durability retinal treatments through a proprietary biopolymer platform, currently advancing multiple candidates through Phase 3 pivotal trials.

GeographiesUnited States, European Union, China, Japan

Customer segmentsSpecialized Healthcare Providers, Patients

Business modelResearch and Development, IP Licensing

SuppliersContract manufacturing organizations, Specialized API suppliers, Clinical trial sites, Regulatory agencies

CustomersSpecialty pharmacies, Hospitals, Ophthalmic clinics, Third-party payors

CountryUnited States of America

Listed2018

Employees107.0

CEOVictor Perlroth

SectorHealthcare

IndustryBiotechnology

Websitekodiak.com

FilingsSEC EDGAR

Questions, answered.

What is Kodiak Sciences Inc's market cap?: Kodiak Sciences Inc (KOD) has a market capitalization of $2.6B and trades on NASDAQ.
Who are Kodiak Sciences Inc's competitors?: Kodiak Sciences Inc's key competitors include Regeneron Pharmaceuticals, Inc., Kalaris Therapeutics, Inc. Common Stock, 4D Molecular Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Kodiak Sciences Inc partner with?: Kodiak Sciences Inc's notable partners include Lonza.
Where is Kodiak Sciences Inc headquartered?: Kodiak Sciences Inc is headquartered in United States of America and employs approximately 107 people. It has been publicly traded since 2018.